MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $84M |
| Revenue Growth (YOY): 2.87% |
| Profit (% of Rev): 81.77% |
| Income (% of Rev): 9.63% |
| Income Growth (YOY): 19.73% |
| Operating Income: $11M |
| Operating Cash Flow: $22M |
| Operating Cash Flow Growth (YoY): 69.31% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $244M |
| Total Liabilities: $63M |
| Cash & Equivalent: $89M |
| Total Debt: $19M |
| Debt/Equity: 0.11 |
| Quick Ratio: 3.53 |
| Current Ratio: 4.10 |
| Price/Book: 4.80 |
| Price/Earnings: 26.82 |
| EBITDA: $11M |
| EPS: 0.0551 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.